Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC). Issue 2 (December 2015) - Drake, Charles; Quinn, David; Dreicer, Robert; Antonarakis, Emmanuel; Shore, Neal; Corman, John; Concepcion, Raoul; Pieczonka, Christopher; Campogan, Dwayne; Fan, Li-Qun; Chang, Nancy; Sheikh, Nadeem; et al.